How many investments has Catalio Capital Management, LP made?

Catalio Capital Management, LP has 106 tracked investments, 14 of which have exited, including 3 dated in the last 24 months.

What stage does Catalio Capital Management, LP invest at?

Catalio Capital Management, LP invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does Catalio Capital Management, LP focus on?

Catalio Capital Management, LP focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.

Where is Catalio Capital Management, LP located?

Catalio Capital Management, LP is headquartered in New York, US.

Does Catalio Capital Management, LP lead rounds?

Catalio Capital Management, LP typically participates in rounds rather than leading them.

Who does Catalio Capital Management, LP co-invest with?

Catalio Capital Management, LP most often shares deals with RA Capital, ARCH Venture Partners, Andreessen Horowitz, among 258 tracked co-investors.

Catalio Capital Management, LP

Crossover fund

New York · Seed–Late Stage · 36 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Catalio Capital Management, LP

3,587 people in our graph share verified history with the Catalio Capital Management, LP team — schools, employers, funds. One of them is your warm intro.

Chris Bischoffunlockedknows Tom V. Brooks · together at Goldman Sachs (overlapped)

×7knows the team · via Goldman Sachs

knows the team · via Johns Hopkins University

knows the team · via Imperial College London

×2knows the team · via Imperial Business School

✨ Fox Verdict

Investment thesis

Catalio invests in innovative healthcare companies at all stages and sizes, spanning the full capital structure across private, public, and credit markets. The firm leverages a network of 45+ venture partners — world-renowned scientist-entrepreneurs — who provide proprietary deal flow, serve as an expert network for due diligence, advise on emerging and disruptive life sciences trends, and offer early exposure to breakthrough technologies. These partners contribute specialized scientific, technological, and clinical expertise and bring a track record of building companies that have generated significant enterprise value.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices France Global New York New York City United Kingdom United States

Source: firm website, verified Sep 15, 2026.

Stage

Seed–Late Stage

New York, New York, US

Leads rounds

Follows

Instruments

Equity · Debt

Founded

2020

Last 12 months

3 investments

AUM

$2.2B

Tracked investments

106

Unicorns

IPOs

Acquisitions

Team · 36 people

from public directories

George C. Petrocheilos· Co-Founder and Managing Partner· New York, New York, United Statesin 𝕏

George Petrocheilos co-founded Catalio Capital Management, where he serves as Managing Partner and focuses on investments in private healthcare companies. He sits on the Investment Committee of the firm's Nexus strategy and on its Management Committee, and previously was a General Partner at Camden Partners Holdings, a private equity firm spun out of T. Rowe Price. He holds a B.A. in Financial Economics from Johns Hopkins University.

g•••@cataliocapital.comreveal

John Henry Iucker· Founding Partner & Head of Credit· New York, New York, United Statesin

John Henry Iucker is a Founding Partner and Head of Credit at Catalio Capital Management, where he focuses on providing senior-secured structured credit to healthcare and biomedical technology companies. He serves on the firm's Structured Opportunities Investment Committee and Management Committee. Before Catalio, he was a Principal and Fixed Income Portfolio Manager at Brown Advisory and held a seat on that firm's private income strategy investment committee. He holds a B.A. in Financial Economics from Johns Hopkins University and is a CFA charterholder.

j•••@cataliocapital.comreveal

Diamantis Xylas· Founding Partner & Head of Research· New York, New Yorkin

Diamantis Xylas is a Founding Partner and Head of Research at Catalio Capital Management, where he leads the research team and invests in private biomedical technology companies. He sits on the investment committee of Catalio's Nexus strategy and the firmwide management committee. Before Catalio, he completed General Surgery residency training at Johns Hopkins Hospital and postgraduate medical and surgical training in London, and served as a visiting research fellow studying bladder cancer genetics at Weill Cornell Medical Center. He holds an MBBS from Imperial College School of Medicine and a BSc in Healthcare Management from Imperial College Business School.

d•••@cataliocapital.comreveal

Isaac Ro· Partner· New York, New York, United Statesin

Isaac Ro is a Partner at Catalio Capital Management. He was previously Executive Chairman of Haystack Oncology (sold to Quest Diagnostics), CFO of Sema4, which he took public in 2021, and CFO of Thrive Earlier Detection (sold to Exact Sciences). Earlier he led U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs and held a similar role at Leerink Partners, and he holds a B.A. in History from Middlebury College.

i•••@cataliocapital.comreveal

R. Jacob Vogelstein· Managing Partner· Bethesdain 𝕏

Jacob Vogelstein co-founded Catalio Capital Management and serves as Managing Partner, focusing on investments in private healthcare companies and sitting on the firm's Nexus strategy Investment Committee and Management Committee. He was previously a General Partner at Camden Partners Holdings, where he invested in biomedical technology, and earlier held faculty positions at Johns Hopkins University's Applied Physics Laboratory and Whiting School of Engineering. He holds a BSc in Bio-Electrical Engineering from Brown University and a PhD in Biomedical Engineering from the Johns Hopkins University School of Medicine.

j•••@cataliocapital.comreveal

Tom V. Brooks· Partner· Baltimore, Maryland, United Statesin

t•••@cataliocapital.comreveal

Adam Riess· Venture Partner· New York, New York

Adam Riess is the Bloomberg Professor of Physics at Johns Hopkins University, with expertise spanning physics and big data. He holds a BS from the Massachusetts Institute of Technology and a PhD from Harvard University. His honors include the 2011 Nobel Prize in Physics, the 2015 Breakthrough Prize in Fundamental Physics, and a 2008 MacArthur Fellowship, and he was elected to the National Academy of Sciences in 2009.

Alan Ashworth· Venture Partner· San Francisco, California𝕏

Alan Ashworth is President of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. His work centers on cancer genetics and therapeutic discovery and development. He holds a BSc from Imperial College of Science and Technology and a PhD from University College London, and is a Fellow of the Royal Society.

Christine E. 'Kricket' Seidman· Venture Partner· San Francisco, California

Christine E. "Kricket" Seidman is the Thomas W. Smith Professor of Genetics and Medicine at Harvard Medical School and Brigham and Women's Hospital, with expertise in genetics and cardiovascular biology and medicine. She earned a BA from Harvard University and an MD from George Washington University School of Medicine, completing her residency at Johns Hopkins and a postdoctoral fellowship at Massachusetts General Hospital. She has been elected to the National Academy of Science and the National Academy of Medicine and co-founded MyoKardia.

Dan Littman· Venture Partner· New York, New York

Dan Littman is the Kimmel Professor of Molecular Immunology at NYU School of Medicine, with expertise in immunology and virology. He holds a BA from Princeton University and an MD and PhD from Washington University in St. Louis, and completed his residency and postdoctoral fellowship at Columbia University. He has co-founded biotechnology companies and received several awards in biomedical science.

David Sinclair· Venture Partner· Boston, Massachusettsin 𝕏

David Sinclair is a Professor of Genetics at Harvard Medical School and Co-Director of the Paul F. Glenn Labs for the Biology of Aging, focusing on longevity and the biology of aging. He holds a BS and PhD from the University of New South Wales and completed a post-doctoral fellowship at MIT. He has co-founded numerous biotechnology companies and authored the New York Times bestseller "Lifespan."

Frances H. Arnold· Venture Partner· Los Angeles, Californiain 𝕏

Frances H. Arnold is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology, with expertise in protein engineering, synthetic biology, and biocatalysis. She holds a BS from Princeton University and a PhD from the University of California, Berkeley, where she also completed a postdoctoral fellowship. Her recognitions include the 2018 Nobel Prize in Chemistry and the National Medal of Technology and Innovation.

Freda Lewis-Hall· Venture Partner· New York, New Yorkin

Freda Lewis-Hall previously served as Chief Medical Officer and Executive Vice President at Pfizer and at Vertex Pharmaceuticals, and as Senior Vice President at Bristol-Myers Squibb. She holds a BA from Johns Hopkins University and an MD from Howard University College of Medicine, and her expertise spans drug development and delivery, bio-pharmaceutical management, health disparities, and psychiatry.

Gordana Vunjak-Novakovic· Venture Partner· New York, New Yorkin 𝕏

Gordana Vunjak-Novakovic is a professor of biomedical engineering and medical sciences at Columbia University, where she leads the Laboratory for Stem Cells and Tissue Engineering. Her research centers on tissue engineering, organs-on-a-chip disease models, and regenerative medicine. She earned her BS, MS, and PhD from the University of Belgrade and is a member of the National Academies of Medicine, Engineering, and Inventors.

Gregg L. Semenza· Venture Partner· Baltimore, Marylandin

Gregg L. Semenza is the C. Michael Armstrong Professor of Genetic Medicine at Johns Hopkins School of Medicine and directs the Armstrong Oxygen Biology Research Center at Johns Hopkins Medicine. His research spans angiogenesis, cancer biology, oxygen biology, and transcriptional regulation. He earned a BA from Harvard College, an MD/PhD from the University of Pennsylvania, completed residency at Duke University Medical Center and a fellowship at Johns Hopkins, and received the 2019 Nobel Prize in Physiology or Medicine.

Henry Brem· Venture Partner· Baltimore, Marylandin

Jeffrey M. Friedman· Venture Partner· New York City

Jim J. Collins· Venture Partner· New York, New York

Jim J. Collins is the Termeer Professor of Medical Engineering & Science at MIT and an Institute Member of the Broad Institute of MIT and Harvard, with expertise in synthetic biology and systems biology. He holds a BA from the College of the Holy Cross and a PhD from the University of Oxford, where he was a Rhodes Scholar. His recognitions include the MacArthur Fellowship and membership in the National Academies of Medicine, Sciences, and Engineering.

Justin Hanes· Venture Partner· Baltimore, Marylandin 𝕏

Justin Hanes serves as Director of the Center of Nanomedicine at Johns Hopkins Medicine, with a research focus on nanomedicine. He holds a BS from the University of California Los Angeles and a PhD from the Massachusetts Institute of Technology. He was elected to the National Academy of Inventors in 2014 and named to MIT Technology Review's 35 Innovators Under 35 in 2003.

Michael A. Rogawski· Venture Partner· Sacramento, Californiain 𝕏

Michael A. Rogawski is a Distinguished Professor in the Department of Neurology at the University of California, Davis School of Medicine. His research focuses on neurological therapeutics, with particular expertise in neuropharmacology, antiepileptic drugs, epilepsy therapies, and headache treatments.

Padmanee 'Pam' Sharma· Venture Partner· Houston, Texas

Sharma is a physician-scientist specializing in immunology, immunotherapy, and genitourinary medical oncology, and serves as Co-Director of the Parker Institute for Cancer Immunotherapy at The University of Texas MD Anderson Cancer Center. She earned a BA and MA from Boston University and an MD/PhD from Pennsylvania State University College of Medicine, completing a residency at New York Presbyterian Hospital, Weill Cornell Medical Center, and a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center. She has co-founded several biotechnology companies and served on numerous scientific advisory boards.

Paula T. Hammond· Venture Partner· Massachusettsin

Paula T. Hammond is an Institute Professor of Chemical Engineering at the Massachusetts Institute of Technology and Dean of Engineering as of January 2026. Her research focuses on using electrostatic interactions and complementary mechanisms to develop functional materials with controlled architecture, particularly in nanomedicine applications including drug delivery, targeted nanoparticle therapeutics, and cancer treatment. Hammond has been elected to the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine, and has received numerous honors including the National Medal of Technology and Innovation, the Benjamin Franklin Medal for Chemistry, and the AIChE Charles M. A. Stine Award.

Philip D. Greenberg· Venture Partner· United States

Philip D. Greenberg is a Professor of Oncology and Immunology at the University of Washington and an Investigator at the Parker Institute for Cancer Immunotherapy at Fred Hutchinson Cancer Research Center. His work spans immunology, immuno-oncology, cancer biology, genetic engineering, and cell therapy. He earned a BA from Washington University in St. Louis and an MD from the State University of New York, and completed his residency and postdoctoral fellowship at the University of California, San Diego.

Raju Kucherlapati· Venture Partner· Weston, Floridain

Raju Kucherlapati is a Professor of Genetics at Harvard Medical School. He earned his PhD from the University of Illinois Urbana-Champaign and completed postdoctoral training at Yale University, following degrees earned in India. He was elected to the National Academy of Medicine and served on the Presidential Commission for the Study of Bioethical Issues from 2009 to 2017.

Samir Mitragotri· Venture Partner· Cambridge, Massachusettsin 𝕏

Samir Mitragotri is the Hiller Professor of Bioengineering at Harvard University, with research expertise in drug delivery and biomaterials. He earned a BS from the Institute of Chemical Technology in India and a PhD from the Massachusetts Institute of Technology, and has been elected to the National Academy of Engineering, the National Academy of Medicine, and the National Academy of Inventors. He has co-founded several life sciences companies.

Sangeeta N. Bhatia· Venture Partner· Cambridge, Massachusettsin 𝕏

Sangeeta N. Bhatia directs the Marble Center for Cancer Nanomedicine at MIT, with research focused on nanomedicine in liver disease and cancer. She holds a BSc from Brown University, an MD from Harvard Medical School, and a PhD from MIT. She has co-founded several biotechnology companies and received recognitions including the Lemelson-MIT Prize and election to the National Academies of Sciences, Medicine, and Engineering.

Solomon H. Snyder· Venture Partner· Baltimore, Marylandin

Thomas C. Südhof· Venture Partner· Stanford, California𝕏

Titia de Lange· Venture Partner· San Francisco, California

Titia de Lange directs the Anderson Center for Cancer Research at Rockefeller University, where she holds the Leon Hess Professorship in Cell Biology and Genetics. Her work spans cancer biology, chromosome biology, cell biology, and genetics. She earned her BA and PhD from the University of Amsterdam and completed postdoctoral training at the University of California, San Francisco.

Matthew Hobson· Analyst· Baltimore, Marylandin

Matthew Hobson is a Principal at Catalio Capital Management, where he focuses on therapeutics and diagnostics investments across the firm's venture and private credit strategies. He joined Catalio at its 2020 founding, having previously been a Postdoctoral Fellow at the Johns Hopkins School of Medicine, where he also earned a PhD in biophysics and biophysical chemistry. He holds a B.S. in chemistry and physics from Emory University.

m•••@cataliocapital.comreveal

Nicholas von Guionneau· Analyst· United Kingdomin

Nicholas von Guionneau is a Principal at Catalio Capital Management, where he makes private credit and venture investments in healthcare companies, with a focus on medtech and neurotherapeutics. Before joining Catalio, he was a Postdoctoral Research Fellow at Johns Hopkins Medicine working on peripheral nerve regeneration and implantable neurodevices, drug delivery systems, and protein therapeutics, and earlier practiced as a clinician at Guy's and St. Thomas' NHS Trust in London. He holds an MBBS and a BSc in Medical Sciences from Imperial College School of Medicine.

n•••@cataliocapital.comreveal

Vicky Sostilio· Vice President of Marketing· New York, New York, United Statesin

Vicky Sostilio is Vice President of Marketing at Catalio Capital Management, covering North America and working with current and prospective investors across Catalio's strategies. She previously served as Head of Investor Relations and Marketing at HealthCor Management, a healthcare-focused long short equity fund, and spent six years at UBS as a Director on the Capital Introduction and Business Consulting team. She holds a B.S. in Finance with a minor in Computer Science from Wake Forest University.

v•••@cataliocapital.comreveal

Will Denehy· Vice President – Europe· Europein

Will Denehy is Vice President of Marketing at Catalio Capital Management UK, covering Europe, and works with current and prospective investors across Catalio's funds. He previously served as Investment Director at Odey Asset Management (2015-2022) and worked in wealth management sales at Fisher Investments (2013-2015). He holds a B.A. in History from the University of Bristol.

w•••@cataliocapital.comreveal

Jenna Glatzer· Analyst· Baltimore, Maryland

Josh Samuelson· Advisor· Fairfield, Californiain

Maria Sirenko· Analyst· New York Cityin 𝕏

Founder mafia

The Catalio Capital Management, LP mafia →

7 people who came through Catalio Capital Management, LP went on to found or lead other companies.

Sangeeta N. BhatiaVenture PartnerFounded Port Therapeutics +3 Thomas C. SüdhofVenture PartnerFounded Recognify Life Sciences Justin HanesVenture PartnerFounded KALA BIO Frances H. ArnoldVenture PartnerFounded Provivi Jim J. CollinsVenture PartnerFounded Sherlock Biosciences Raju KucherlapatiVenture PartnerFounded KEW Group Samir MitragotriVenture PartnerFounded i2O Therapeutics

What they invest in

from 79 of 106 portfolio companies

Biotech ×62Healthtech ×52Medical Devices ×36Digital Health ×19AI & Machine Learning ×17Deep Tech ×15Mental Health ×4Longevity ×3

HQs:United States×56United Kingdom×2Switzerland×1

Who they back

founder profiles across 55 portfolio companies

42%

solo founders

23 of 55 mapped founding teams

39%

repeat founders

of 70 founders with career history

~1 yr

old at investment

median across 13 dated deals

Founding team size:solo founder×232 founders×113 founders×154+ founders×6

Where their founders studiedfrom 68 founders with education data

Stanford University ×6University of California, Berkeley ×5Harvard Medical School ×4Massachusetts Institute of Technology ×4Stanford University Graduate School of Business ×4Harvard University ×3MIT Sloan School of Management ×3The Johns Hopkins University ×3

What their founders studiedfrom 64 founders with field-of-study data

Life Sciences ×23Engineering ×17Business & Management ×11Computer Science ×8Medicine ×8Chemistry ×6Mathematics & Statistics ×5Economics ×4

Where their founders worked beforefrom 70 founders with career history

Stanford University ×4Brigham and Women's Hospital ×3Allergan ×2Blackrock Microsystems ×2Delfi Diagnostics ×2General Catalyst ×2Harvard Medical School ×2Iambic Therapeutics, Inc. ×2

32 founders hold a PhD · 2 hold an MBA (of 69 with degree data)

Investments · 106 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 1 2023 · 3 2022 · 2 2021 · 2 2020 · 1 2018 · 1 2016 · 1 2015 · 1 2014 · 115 dated

AtaiBeckleyatai.lifeNASDAQ: ATAI

AtaiBeckley develops rapid-acting mental health treatments and therapies for patients with difficult-to-treat mental health conditions.

BiotechDeep TechDigital HealthMedical DevicesMental Health

Srinivas Rao(Co-Founder and Chief Executive Officer)inChristian Angermayer(Founder and Chairman of the Board)

Co-investorsAble Partners Alpha Wave Global FJ Labs Future Ventures Leafy Tunnel Nucleus Adventure Capital +4 more

Avalyn Pharma Incavalynpharma.com inNASDAQ: AVLN

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera Partners F-Prime Capital InVivium Capital Norwest Venture Partners RiverVest Venture Partners SR One Capital Management +9 more

Compass Pathwayscompasspathways.com in 𝕏NASDAQ: CMPS

Compass Pathways develops novel treatments for mental health conditions, with a focus on psychedelic-assisted therapies supported by rigorous clinical research.

BiotechDigital HealthHealthtechMedical DevicesMental Health

Kabir Nath(CEO)

Co-investorsAble Partners Aisling Capital Noetic OMX Ventures Vivo Capital Jam Fund

Fractylfractyl.com in 𝕏NASDAQ: GUTS

Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.

BiotechHealthtechMedical DevicesLexington, US

HARITH RAJAGOPALAN(Executive Officer, Director)inJAY CAPLAN(Executive Officer, Director)inJay Caplan(Executive Officer, Director)in Harith Rajagopalan(Co-Founder and CEO)in LISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in

Co-investorsBessemer Venture Partners Emergent Medical Partners, LLP Mithril Capital Management Domain Associates General Catalyst MITHRIL +2 more

Freenomefreenome.com in 𝕏NASDAQ: FRNMOct 2015

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGabriel Otte(Director)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRA Capital Agent Capital AME Cloud Ventures Andreessen Horowitz Artis Ventures Asset Management Company +9 more

Kardigankardigan.bio inNASDAQ: KARD

Kardigan develops targeted cardiovascular treatments through a discovery and translational research platform, with a pipeline of late-stage drug candidates aimed at functional cures for cardiovascular disease.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsARCH Venture Partners T. Rowe Price

Neumora Therapeuticsneumoratx.com in 𝕏NASDAQ: NMRASep 2020

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

BiotechDeep TechDigital HealthMedical DevicesWatertown, US

Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)

Co-investorsARCH Venture Partners F-Prime Capital K2 HealthVentures Mercury Fund Premier Partners SoftBank Vision Fund +3 more

Parabilis Medicinesparabilismed.com inNASDAQ: PBLS

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)in

Co-investorsARCH Venture Partners Foresite Capital Frazier Life Sciences General Catalyst Nextech Invest RA Capital +7 more

Protara Therapeuticsprotaratx.com inNASDAQ: TARA

Protara develops transformative therapies for patients with cancer and rare diseases, applying modern scientific and manufacturing advancements to accelerate drug development.

BiotechHealthtechMedical Devices

Jesse Shefferman(President, Chief Executive Officer and Director)inPatrick Fabbio(Chief Financial Officer)inJacqueline Zummo(Chief Research & Development Officer)inWilliam Conkling(Chief Commercial Officer)Leonardo Nicacio(Chief Medical Officer)

Recursion (NASDAQ: RXRX)recursion.com in 𝕏NASDAQ: RXRX

Recursion applies computational and data-driven approaches to biological science, aiming to accelerate drug discovery and develop new treatments.

AI & Machine LearningBiotechData & InfrastructureDeep TechMedical DevicesSalt Lake City, US

Chris Gibson(Co-founder, Chairman of the Board)in Blake C. Borgeson(Executive Officer, Director)inDean Y. Yi(Executive Officer, Director)Najat Khan(Chief Executive Officer)in

Co-investorsDCVC (Data Collective)Lux Capital Baillie Gifford Air Street Capital Amplify Partners Central Texas Angel Network +14 more

9am Healthjoin9am.com in

9amHealth provides virtual care for cardiometabolic conditions, offering weight management, diabetes care, and heart health treatment that combines prescription medication (including GLP-1s), lifestyle coaching, and lab testing.

Digital HealthHealthtechWellness & FitnessEncinitas, US

Frank Westermann(Executive Officer, Director)in Anton Kittelberger(Founder)inMichael Hofner(Executive Officer)inAvantika Waring(Executive Officer)Paul Geevarghese(Executive Officer)in Bernhard Schandl(Executive Officer)in

Co-investors7wire Ventures Calm/Storm VC Define Ventures Habitat Partners Hansmann Family Office PUSH Ventures +2 more

Abridgeabridge.com in 𝕏

Abridge builds AI software that converts clinical conversations into structured insights for healthcare providers.

AI & Machine LearningDigital HealthHealthtechPhiladelphia, US

Shiv Rao(Founder & CEO)inSandeep Konam(Cofounder)in Shiv (Shivdev) Rao(Founder)inJulia Chapin(Executive Officer)Sagar Sanghvi(Executive Officer)in

Board Andy Weissman(Director)in

Co-investorsAlpha Square Group alphabet angels Andreessen Horowitz Bessemer Venture Partners CapitalG Collective Liquidity +21 more

AdvanCelladvancell.com.au inJun 2026

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)in Aaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsBain Capital Life Sciences Proto Axiom SV Health Investors Tenmile Abingworth Ally Bridge Group +2 more

Alentisalentis.ch in

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)in Luigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in

Co-investorsAvego BioScience Capital BioMedPartners Frazier Life Sciences Jeito Capital Longitude Capital Novo Holdings +5 more

Amalgamamalgamrx.com in

Amalgam builds a modular, AI-powered Software as a Medical Device (SaMD) platform and EHR-integrated solutions for life sciences companies, health plans, and providers to support clinical decisions, patient engagement, and digital therapeutics.

AI & Machine LearningDigital HealthHealthtechWilmington, US

Ryan Sysko(Founder)in

BoardSONNY VU(Director)JEFFREY P. COURTNEY(Director)

Co-investorsCVS Health Ventures Supermorpheus

Arriventarrivent.com inDec 2022

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)in Brent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsForesite Capital General Catalyst HongShan Capital Group LAV Lilly Asia Ventures OrbiMed +2 more

ATAIatai.com

AtaiBeckley develops rapid-acting mental health treatments for patients with difficult-to-treat conditions through rigorous scientific research and clinical applications.

BiotechDigital HealthHealthtechMental Health

Srinivas Rao(Co-Founder and Chief Executive Officer)inChristian Angermayer(Founder and Chairman of the Board)

Co-investorsatai Life Sciences AtaiBeckley

Audicusaudicus.com in

New York-based D2C provider of high-quality hearing aids in the US.

HealthtechNew York, US

Patrick Freuler(Executive Officer, Director)inAndre Sequin(Executive Officer)

Co-investorsECONA AG TIA Ventures HOWZAT Partners

Aviceda Therapeutics in

BiotechCambridge, US

Mohamed Genead(Executive Officer, Director)in Michael Tolentino(Executive Officer, Director)inDavid Callanan(Executive Officer)inTarek Hassan(Executive Officer)inDerek Kunimoto(Executive Officer)in

BoardDavid Guyer(Director)

Co-investorsJeito Capital Avoro Capital Advisors Longitude Capital Omega Funds

Axena Healthaxenahealth.com in

Axena Health develops digital therapeutic devices for women's pelvic health, specifically treating urinary and fecal incontinence through at-home pelvic floor muscle training.

Digital HealthFemTechHealthtechMedical DevicesAuburndale, US

Samantha Pulliam(CEO and Chief Medical Officer)inVincent Ricci(Executive Officer)Jim O'Connor(Executive Officer)inShacey Petrovic(Executive Officer, Director)inEileen Maus(Executive Officer, Director)in

BoardJonathan Dean(Director)

Co-investorsCross-Border Impact Ventures Avestria Ventures

Bayesian Healthbayesianhealth.com in 𝕏

Bayesian Health develops clinical artificial intelligence for real-time patient monitoring and clinical decision support.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Suchi Saria(Founder and CEO)in

Co-investorsAndreessen Horowitz Epsilon Health Investors Health2047 Capital Partners LLC Lifeforce Capital MemorialCare Innovation Fund

Blackrock Neurotechblackrockneurotech.com in 𝕏

Blackrock Neurotech develops a neurotechnology platform, including brain-computer interface systems, aimed at improving patient lives and treating neurological conditions.

BiotechDeep TechMedical Devices

Florian Solzbacher(Co-Founder & CSO)in Marcus Gerhardt(Co-Founder & CEO)in Thomas Thiele(CFO)in

BoardChristian Angermayer(Co-Chairman)Tim Sievers(Co-Chairman)

Co-investors2050 Capital Forepont Capital Partners Tether

Cambrian Biocambrianbio.com in 𝕏

Cambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR.

BiotechHealthtechLongevityNew York, US

James G. Peyer(Executive Officer, Director)in James Peyer(CEO, Founder, Board Director)in James Peyer, PhD(Founder)inMark Nuttall(Chief Business Officer)in Ruth Thieroff-Ekerdt(Chief Medical Officer)in William DeVaul(Executive Officer)in

Co-investorsAlumni Ventures Future Ventures Khosla Ventures Korify Capital Sprint Vc Strawberry Creek Ventures +2 more

Carbon Healthcarbonhealth.com in 𝕏

Carbon Health operates a chain of clinics offering urgent care, primary care, and chronic condition management, combining technology with in-person care to provide broader access to health services.

Digital HealthHealthtechMedia & Entertainment

Eren Bali(Founder)in Greg Burrell inTom Berry

Co-investors500 Emerging Europe 500 Global Akkadian Ventures Annex Investments Builders VC DCVC (Data Collective)+17 more

Celsius Therapeuticscelsiustx.comacquired by AbbVie

Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine.

HealthtechCambridge, US

Tariq Kassum(Executive Officer, Director)in Michael Boretti(Executive Officer)in Christoph Lengauer(Executive Officer, Director)in

Co-investorsFast Track Initiative Alexandria Casdin Capital GV (Google Ventures)Third Rock Ventures

Centenara Labscentenara.com in 𝕏

Centenara Labs is a longevity-focused drug discovery company that translates research on the biology of aging into therapies intended to improve healthy aging and extend lifespan.

BiotechHealthtechLongevity

Christian Angermayer(Founder)in

Co-investorsKorify Capital P53 Invest

Centrexion Therapeuticscentrexion.com in 𝕏

Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development.

BiotechHealthtechBaltimore, US

James N. Campbell(President, Chief Scientific Officer)in Kerrie L. Brady(Executive Officer)inGregg Beloff(Executive Officer)Jeffrey B. Kindler(Chief Executive Officer)in Charles Oh(Chief Medical Officer)inSmital Shah(Acting CBO)in

Co-investorsEFung Capital New Enterprise Associates (NEA)Quan Capital 6 Dimensions Capital Avoro Capital Advisors Exome Asset Management

Character Biocharacterbio.com in

Character Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases.

AI & Machine LearningBiotechDigital HealthJersey City, US

Cheng Zhang(CEO, Co-Founder)inMarcel van der Brug(Scientific Advisor, Co-Founder)inNick Johnson(Technology Advisor, Co-Founder)in Daniel Elgort(Chief Data and Analytics Officer)in Laura Carter(Chief Scientific Officer)inRobert Kim(Chief Medical Officer)in

Co-investorsaMoon Sanofi Ventures Innovation Endeavors Luma Group Cantos Ventures Duke Capital Partners +4 more

Claris Bioclarisbio.com in

Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.

BiotechHealthtechMedical DevicesJersey City, US

Clarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)Susan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)

Co-investorsRA Capital Sofinnova Ventures Catalio Capital Management Novo Holdings Samsara BioCapital

Clasp Therapeuticsclasptx.com in

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCure Ventures Vivo Capital Catalio Capital Management Novo Holdings Third Rock Ventures

Cresiloncresilon.com in 𝕏

Cresilon develops plant-based flowable hemostatic gel technology that controls bleeding within seconds without manual pressure, with products for veterinary care (VETIGEL) and human trauma (TRAUMAGEL).

BiotechHealthtechMedical DevicesNew MaterialsBrooklyn, US

Isaac Miller(Co-founder)inJoe Landolina(Co-founder & CEO)in Scott Levine(Executive Officer)in

Co-investorsDorm Room Innovating Capital

eGenesisegenesis.com

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

Board George M. Church(Director)

Co-investorsAlta Partners ARCH Venture Partners Khosla Ventures OUP (Osage University Partners)b2venture Kendall Capital Partners +1 more

Ensomaensoma.comFeb 2021

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.

BiotechHealthtechMedical DevicesBoston, US

Albert Seymour(Director)

Board Kush Parmar(Executive Officer, Director)in Paula Soteropoulos(Director)Stephen Knight(Director)in

Co-investors5AM Ventures Aju IB Invesment Corporation Delos Capital F-Prime Capital Solasta Ventures Alexandria +7 more

Envedaenvedabio.com

Clinical-stage biotech using AI and metabolomics to decode natural chemistry and discover small-molecule medicines.

Viswa Colluru, PhD(Founder)in

Co-investorsAir Street Capital Boulder Ventures FPV Hummingbird Ventures JAZZ Venture Partners Kinnevik +7 more

Erisyonerisyon.com in 𝕏

Erisyon is a biotechnology company that develops technology to advance scientific and health discoveries, building on research from the University of Texas at Austin's Center for Systems and Synthetic Biology.

BiotechDeep TechHealthtech

Co-investorsFoothill Ventures

Fogpharmafogpharma.com in

FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases.

BiotechBoston, US

Gregory L Verdine(Executive Officer, Director)Mathai Mammen(CEO, President and Chairman)in

Co-investorsHorizons Ventures GV (Google Ventures)venBio Global Strategic

Georgiamunegeorgiamune.com inJul 2026

Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases.

BiotechDeep TechHealthtechGaithersburg, US

Samir N. Khleif(Founder & CEO)inRamy Ibrahim(Chief Medical and Strategy Officer)inMikayel Mkrichyan(Senior Vice President of Science and Discovery)Sarah Sharman(Vice President of IP Legal Affairs)

BoardSean Parker(Director)Elena Viboch(Director)in

Co-investorsHAWKTAIL Lauder Partners Prevail Venture Capital General Catalyst Johnson & Johnson Innovation – JJDC

GlycoEraglycoera.com in 𝕏

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)in

Co-investors5AM Ventures LifeArc Ventures Roche Venture Fund Sixty Degree Capital Sofinnova Partners Agent Capital +1 more

Hippocratic AIhippocraticai.com in 𝕏

Hippocratic AI develops generative AI agents designed for healthcare delivery, working with hospital systems, health plans, and life sciences companies to support clinical decision-making and patient care.

AI & Machine LearningDigital HealthHealthtech

Munjal Shah(Chief Executive Officer, Co-founder)inDr. Meenesh Bhimani(Chief Medical Officer, co-founder)in Vishal Parikh(Chief Product Officer, Co-founder)in Subho Mukherjee(Chief Science Officer, Co-founder)in Saad Godil(Founder)in Subhabrata (Subho) Mukherjee(Founder)in

Co-investorsAndreessen Horowitz General Catalyst Avenir Growth Capital Founders Circle Capital Greycroft Hakluyt Capital +4 more

Iambiciambic.ai in

Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.

AI & Machine LearningBiotechDeep TechSan Diego, US

Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)in Thomas Miller(Founder)inNeil Josephson(Chief Medical Officer)in Pete Olson(Chief Scientific Officer)in Michael Secora(Chief Financial Officer and Chief Corporate Development Officer)in

Co-investorsAscenta Capital Abingworth Catalio Capital Management Alumni Ventures Coatue Management Eisai Innovation, Inc.+4 more

Imbriaimbria.com in

Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.

BiotechDigital Health

Alvin Shih(CEO)in Albert M. Kim(Chief Medical Officer)in

Co-investorsAN Venture Partners RA Capital Sanofi Ventures SV Health Investors Catalio Capital Management

Immunaiimmunai.com in 𝕏

Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development.

AI & Machine LearningBiotechData & InfrastructureNew York City, US

Co-investorsGefen Capital Koch Disruptive Technologies Meron Capital Perot Jain TLV Partners Viola Ventures +2 more

Imperative Care Incimperativecare.com in 𝕏

Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.

HealthtechMedical DevicesCampbell, US

Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in

BoardJames Rogers(Director)Stacy Enxing Seng(Director)

Co-investorsAscension Ventures Bain Capital Life Sciences Delos Capital FemHealth Ventures Lightstone Ventures

Insightecinsightec.com in 𝕏

Insightec develops Exablate Neuro, an MRI-guided focused ultrasound platform that treats Essential Tremor and tremor-dominant Parkinson's Disease through an incision-free outpatient procedure.

HealthtechMedical DevicesTirat Carmel

Roni Karie(Vice President - Finance)Shirel Aroshase(Vice President - Human Resources)inEyal Zadicario(General Manager)inMenashe Frank(Vice President - Legal)in Jun (Jim) Tao(Chief Operating Officer)in Maurice R. Ferre(Chairman and Chief Executive Officer)in

Co-investorsExigent Capital GEOC Jazzya Investments Koch Disruptive Technologies Krillion Ventures Peregrine Ventures +7 more

Kailerakailera.com in 𝕏

Kailera develops obesity management medications, including GLP-1 and multi-agonist receptor peptides and small molecules, with a global development pipeline led by injectable and oral formulations of ribupatide.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Bain Capital Life Sciences

Lassen Therapeuticslassentherapeutics.com in

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

Biotech

David King(Co-Founder & CSO)in Maria Fardis(CEO)in Cadmus C. Rich(Chief Medical Officer)in Elaine Stracker(General Counsel)in

Co-investorsAlta Partners DC Investment Partners Longitude Capital Longwood Fund Biotechnology Value Fund Catalio Capital Management +2 more

Leo Cancer Careleocancercare.com in 𝕏

Leo Cancer Care develops upright radiotherapy and particle therapy solutions that integrate CT imaging with patient positioning systems.

Deep TechHardwareHealthtechMedical Devices

Stephen Towe(Founder)in

Co-investorsYu Galaxy Catalio Capital Management Mana Ventures Serra Ventures

Lifesproutbiolifesproutbio.comFeb 2018

LifeSprout develops synthetic materials that mimic the body's own tissues for aesthetic and regenerative medicine, creating products to treat patients with soft tissue loss from aging, cancer, and metabolic disease.

BiotechMedical DevicesNew MaterialsBaltimore, US

Hai-Quan Mao(Co-founder, PhD)Sashank Reddy(Co-founder, MD, PhD)Kevin Colbert(Co-founder, Business Development)inRuss Martin(Co-founder, Head of R&D, PhD)inAdam Gridley(Executive Chairman, MBA)

Co-investorsEmerald Development Managers Maryland TEDCO TEDCO

Lila Scienceslila.ai 𝕏

LILA Sciences builds AI systems for autonomous scientific research and discovery across medicine, materials, energy, and defense sectors.

AI & Machine LearningBiotechDeep TechSaaS

Co-investorsAlumni Ventures Dauntless Ventures Flagship Pioneering March Capital Partners Modi Ventures WAGMI Ventures +3 more

Metagenomimetagenomi.co in 𝕏

Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.

BiotechDeep TechMedical DevicesBerkeley, US

Brian Thomas(Executive Officer, Director, Promoter)in

Board Andrew Farquharson(Director)inJak Knowles(Director)

Co-investorsRA Capital Sozo Ventures Agent Capital Frazier Life Sciences Humboldt InCube Ventures +5 more

NextPoint Therapeuticsnextpointtx.com in 𝕏

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.

BiotechHealthtechAustin, US

Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)in Ivan Cheung(Chief Executive Officer)in Leena Gandhi(Chief Medical Officer)in Tatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)

Co-investorsMPM BioImpact Sanofi Ventures Catalio Capital Management Invus Leaps by Bayer Sixty Degree Capital

Noetiknoetik.ai in 𝕏

Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets.

AI & Machine LearningBiotechHealthtechSouth San Francisco, US

Jacob Rinaldi(Executive Officer, Director, Promoter)inRonald Alfa(Executive Officer, Director, Promoter)Ron Alfa, MD, PhD(Founder)in

Board James Hardiman(Director)in Amy Schulman(Director)in

Co-investors11.2 Capital Breakout Labs Breakout Ventures EPIC VENTURES Linearis Ventures North South Ventures +5 more

Octant Biooctant.bio in 𝕏

Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US

Sri Kosuri(Co-founder)inRamsey Homsany(Founder)in

Co-investorsAndreessen Horowitz +ND Capital 8VC Carbon Silicon Fifty Years Flucas Ventures +7 more

Odyssey Therapeuticsodysseytx.com in 𝕏

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)in

Board Jill Carroll(Director)in Carl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in

Co-investorsActivant Capital Ascenta Capital Balderton Capital Foresite Capital Global BioAccess Fund GreatPoint Ventures +8 more

Oncusp Therapeuticsoncusptx.com in

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.

BiotechMedical DevicesNew York, US

Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)Bing Yuan, Ph.D., MBA(Co-Founder, Chief Executive Officer)Eric Slosberg, Ph.D.(Co-Founder, Chief Development Officer)Andy Fu, PharmD, MBA(Co-Founder, Chief Business Officer)

Co-investorsOrbiMed F-Prime Capital Sofinnova Ventures De Novo Ventures Insight Partners NVIDIA

OpenEvidenceopenevidence.com

AI company developing a medical search engine used by physicians for clinical decision support.

Daniel Nadler(Founder & CEO)inZachary Ziegler(Founder)

Co-investorsAlkeon Innovation Amity Ventures Andreessen Horowitz Breyer Capital Coatue Management Cold Start Ventures +16 more

Orasis Pharmaceuticalsorasis-pharma.com in 𝕏

Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.

BiotechHealthtechMedical Devices

Co-investorsArboretum Ventures Maverick Ventures Israel Visionary Ventures Catalio Capital Management Johnson & Johnson Innovation – JJDC LifeSci Venture Partners +1 more

Perfuse Therapeuticsperfusetherapeutics.com in

Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.

BiotechHealthtechMedical DevicesSan Francisco, US

Sevgi Gurkan, MD(Founder, Chief Executive Officer, and Member of the Board of Directors)in

BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in

Co-investorsOrbiMed Access Biotechnology Hatteras Venture Partners LAV Lilly Asia Ventures Hatteras

Personal Genome Diagnosticspersonalgenome.com in 𝕏

A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.

BiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Executive Officer, Director, Promoter)inLuis A. Diaz, Jr.(Executive Officer, Director, Promoter)Sam Angiuoli(Executive Officer)in Sian Jones(Executive Officer)inLisa Kann(Executive Officer)inAnthony Newton(Executive Officer)

Co-investors3B Future Health Fund Co-Win Ventures New Enterprise Associates (NEA)Windham Capital Partners Vensana Capital

Pheast Therapeuticspheast.com in 𝕏Oct 2025

Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.

BiotechHealthtechMedical DevicesRedwood City, US

Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)in Roy Maute(Cofounder & Chief Executive Officer)in

BoardJacob Vogelstein(Director)Steven Gillis(Director)in

Co-investorsARCH Venture Partners Alexandria Catalio Capital Management

Pillar Biosciencespillarbiosci.com inMay 2021

Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics.

BiotechDigital HealthHealthtechMedical DevicesNatick, US

Shawn Liu(Director)Hui Yang(Director)Gang Song(Executive Officer, Director)Zhaohui Wang(Director)Robert Forrester(Director)inHong Fang Song(Director)

Co-investorsHB Ventures Bain Capital Life Sciences Soleus Capital

Pink Dxpinkdx.com in 𝕏Sep 2023

PinkDx is a diagnostics company developing tests, led by a leadership team spanning scientific, medical, and business functions.

BiotechDigital HealthFemTechIndianapolis, US

Richard T. Kloos(Chief Medical Officer)inTimothy McMeekan(Co-Founder, Chief Financial Officer, and Chief Business Officer)Giulia Kennedy(Co-Founder and Chief Scientific Officer)Isaac Ro(Director)in Risa Stack(Director)inEric Wang(Executive Officer)

Co-investorsBEVC Blue Venture Funds Mountain Group Capital Sandbox Industries

Port Therapeuticsporttherapeutics.com in

Port Therapeutics is a company focused on cancer immunotherapy development.

BiotechHealthtech

Lena Gamboa(Head of Cancer Immunotherapy)in Steve Altschuler(Executive Chair)in

PrognomIQprognomiq.com in 𝕏

PrognomiQ is a clinical-stage company developing blood-based tests for early detection and treatment of cancer and other complex diseases using multi-omics data.

AI & Machine LearningBiotechHealthtechSan Mateo, US

Philip Ma, Ph.D.(Executive Officer, Director)Philip Ma(Chief Executive Officer & Founder)inOmid Farokhzad(Chair of the Board of Directors)inBrian Koh, M.D.(Executive Officer)inDavid Siewers(Chief Financial Officer)inBrian Koh(Chief Medical Officer)in

Co-investorsaMoon Wing Maverick Ventures

ProSomnusprosomnus.com inSep 2023

ProSomnus offers oral appliance devices for treating obstructive sleep apnea and snoring, positioned as an alternative to CPAP machines.

Digital HealthHealthtechMedical DevicesWellness & FitnessPleasanton, US

Leonard Liptak(Executive Officer, Director)Sung Kim(Executive Officer)Jason Orchard(Director)Steven Pacelli(Director)Heather Rider(Director)Laing Rikkers(Executive Officer, Director)

Co-investorsCatalio Capital Management Spring Mountain Capital

Recognify Life Sciencesrecognify.life

Recognify is a biotech company developing therapeutic and diagnostic products for CNS disease, oncology, and infectious disease.

BiotechDigital HealthMental Health

Gary Walker(Founder, VP Clinical Development)in Thomas C. Südhof(Founder, Chairman of SAB)Angela Macfarlane(Founder, Board Member, Business Advisor)Matt Pando(Founder, CEO/President)in

Co-investorsatai Life Sciences

Reflexionmedicalreflexion.com in 𝕏

RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.

BiotechHealthtechMedical DevicesHayward, US

Samuel Mazin(Executive Officer, Director)inAkshay Nanduri(Executive Officer, Director)in

Board Jay Watkins(Director)in

Co-investorsAscension Ventures Pfizer Venture Investments Sofinnova Partners Sonder Capital Venrock Sonder Futures

Rejuveronrejuveron.com in 𝕏

Centenara Labs develops longevity drugs and therapies by translating aging research into novel medical treatments aimed at improving healthy aging.

BiotechDeep TechHealthtechLongevity

Christian Angermayer(Founder)Shannon Thyme KlingerEtienne

Co-investorsQC·VENTURES

Resilienceresilience.com 𝕏

Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.

Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US

William S. Marth(Chief Executive Officer)William S. Marth, RPh., MBA(President & CEO)

Board Robert Nelsen(Chairman, Resilience; Founder, ARCH)

Co-investors8VC ARCH Venture Partners GV (Google Ventures)Koch Disruptive Technologies Lux Capital Magnetic Ventures +5 more

Rhapsogenrhapsogen.com

Rhapsogen is developing a precision biologic therapy aimed at treating autoimmune diseases, focused on efficacy, safety, and durability.

BiotechHealthtech

Co-investorsCatalio Capital Management

Satellite Biosatellite.bio

Satellite Bio develops an off-the-shelf cell therapy that delivers functional liver cells (hepatocytes) into the body, where they engraft to restore liver function.

BiotechHealthtechCambridge, US

Christopher Chen(Director, Promoter)inThomas Lowery(Executive Officer)

BoardEllie McGuire(Director)Ling Wong(Director)Sujata Bhatia(Director)William Young(Director)

Co-investorsAlumni Ventures aMoon Lightspeed Venture Partners Highbury Holdings Polaris Partners S32

Septernasepterna.com inJun 2023

Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in

Co-investorsRA Capital Samsara BioCapital Vertex Ventures HC Third Rock Ventures

SetPoint Medicalsetpointmedical.com in 𝕏

SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs.

BiotechHealthtechMedical DevicesValencia, US

Murthy Simhambhatla(CEO)inDavid Chernoff(Chief Medical Officer (MD))Yaakov Levine(PhD)inRohan Seth(Executive Officer)in

BoardBlake Wu(Director)in Juan-Pablo Mas(Director)in

Co-investorsAlly Bridge Group New Enterprise Associates (NEA)Norwest Venture Partners Topspin Partners Citta Capital Lightstone Ventures +5 more

Sherlock Biosciencessherlock.bio in 𝕏

HealthtechCambridge, US

Rahul Dhanda(Executive Officer, Director)in James Collins(Director)David Walt(Director)in

Board Issi Rozen(Director)in

Co-investorsIllumina Ventures Catalio Capital Management Good Ventures GV (Google Ventures)Northpond Ventures Novalis LifeSciences

Sidera Biosiderabio.com

Sidera Bio is a biotechnology company using human genetics to develop new medicines for patients.

Biotech

Co-investorsRA Capital Forbion Novo Holdings

Singular Genomics Systemssingulargenomics.com in 𝕏Acquired

Singular Genomics develops spatial pathology technology to map molecules and cells directly in tissue for disease characterization.

BiotechDeep TechMedical Devices

John Stark(CEO)Aaron Berlin(CTO)in

Co-investorsARCH Venture Partners Coatue Management F-Prime Capital

Sisu Global Healthsisuglobalhealth.comApr 2016

HealthtechBaltimore, US

Carolyn Reed Yarina(Executive Officer, Director)Katherine Kirsch(Executive Officer, Director)Gillian Henker(Executive Officer, Director)in

Co-investorsBelle Impact Fund Golden Seeds

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Ashvattha TherapeuticsAutomataAVAVAB WellBeacon Biosignals Cage PharmaceuticalsCartographyCompassDianthusDNA ScriptElektrofieNeuraHaystack OncologyMedraMindXMonimoi TherapeuticsNeumoraOrpherisOspriPAIGE.AI, Inc.Perceive BiotherapeuticsPGDxProtoAxiomRoshal ImagingSanguine BiosciencesSensei BioSentonixSickbaySomethings

Exits · 14

10 IPOs · 4 acquisitions · showing 13

AtaiBeckleyNASDAQ: ATAIAvalyn Pharma IncNASDAQ: AVLNCompass PathwaysNASDAQ: CMPSFractylNASDAQ: GUTSFreenomeNASDAQ: FRNMKardiganNASDAQ: KARDNeumora TherapeuticsNASDAQ: NMRAParabilis MedicinesNASDAQ: PBLSProtara TherapeuticsNASDAQ: TARARecursion (NASDAQ: RXRX)NASDAQ: RXRXCelsius Therapeuticsacq. by AbbVieElektrofiacq. by Halozyme TherapeuticsPGDxacq. by Labcorp

Portfolio news

latest coverage across their companies

Septerna at Wells Fargo conference: platform bets and pipeline catalysts By Investing.com

Septerna · investing.com · Sep 8, 2026

How Investors Are Reacting To AtaiBeckley (ATAI) Rising Revenue But Deepening Net Losses - Simply Wall St News

ATAI · simplywall.st · Aug 20, 2026

Government Strategy Is Shaping the Global Brain-Computer Interface Race - Neurotech Reports

Blackrock Neurotech · neurotechreports.com · Aug 20, 2026

Enveda’s exercise-simulating obesity tablet clears early clinical test - BioSpace

Enveda · biospace.com · Aug 19, 2026

Seer (SEER) Q2 2026 Earnings Call Transcript - AOL

PrognomIQ · aol.com · Aug 18, 2026

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - Ticker Report

Arrivent · tickerreport.com · Aug 17, 2026

The 19 Largest Global Startup Funding Rounds of July 2026 – AlleyWatch

AdvanCell · alleywatch.com · Aug 13, 2026

Recursion Pharmaceuticals, Inc. $RXRX Stake Increased by California State Teachers Retirement System - Defense World

Recursion (NASDAQ: RXRX) · defenseworld.net · Aug 13, 2026

Frequently asked questions

How many investments has Catalio Capital Management, LP made?: Catalio Capital Management, LP has 106 tracked investments, 14 of which have exited, including 3 dated in the last 24 months.
What stage does Catalio Capital Management, LP invest at?: Catalio Capital Management, LP invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Catalio Capital Management, LP focus on?: Catalio Capital Management, LP focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is Catalio Capital Management, LP located?: Catalio Capital Management, LP is headquartered in New York, US.
Does Catalio Capital Management, LP lead rounds?: Catalio Capital Management, LP typically participates in rounds rather than leading them.
Who does Catalio Capital Management, LP co-invest with?: Catalio Capital Management, LP most often shares deals with RA Capital, ARCH Venture Partners, Andreessen Horowitz, among 258 tracked co-investors.

Images

Co-investors · 12

Catalio Capital Management

Catalio is a software platform that uses AI to automatically extract and document business logic from legacy and modern systems, creating living specifications that stay current as software evolves.

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 7

Kardigan Neumora Therapeutics Parabilis Medicines eGenesis Pheast Therapeutics Resilience Singular Genomics Systems

$50K – $250M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

Both backed · 6

Freenome Abridge Bayesian Health Hippocratic AI Octant Bio OpenEvidence

$500K – $50M

Alumni Ventures

Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.

Both backed · 5

Beacon Biosignals Cambrian Bio Iambic Lila Sciences Satellite Bio

$100K – $10M

Polaris Partners

Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.

Both backed · 4

Fractyl Freenome Noetik Satellite Bio

$500K – $5M

Sequoia Capital

Sequoia Capital is a venture capital firm that partners with founders to build technology companies.

Both backed · 3

Carbon Health OpenEvidence Orasis Pharmaceuticals

$4.4M – $214M

Third Rock Ventures

Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.

Both backed · 3

Celsius Therapeutics Clasp Therapeutics Septerna

$100K – $5M

Abingworth

Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.

Both backed · 2

AdvanCell Iambic

$15M – $30M

Vivo Capital

Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'

Both backed · 2

Compass PathwaysClasp Therapeutics

$10M – $50M

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 1

NextPoint Therapeutics

$1M – $15M

Hatteras Venture Partners

Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.

Both backed · 1

Perfuse Therapeutics

$500K – $4M

Nexus Venture Partners

Nexus Venture Partners invests in early and early growth stage companies operating in India and the United States across multiple sectors. The firm was founded by entrepreneurs with experience building companies.

$500K – $10M

Firms observed investing alongside Catalio Capital Management, LP, from public investor directories. Shared companies are the overlap with Catalio Capital Management, LP's recorded portfolio.

Similar investors

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Lumira Ventures

Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.

$1M – $10M

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

$1M – $75M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Seed Investors & VC Firms in North America Investors & VC Firms in Europe Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States Investors & VC Firms in Global